Loading…
Operates in Pharma — Production. Per the activity note to the FY2024 annual report, the company produces pharmaceutical preparations.
Group parent — controls 1 company · ownership
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|
| 11,787 | 13,399 | 16,583 | 16,848 | 18,458 | 15,356 | 19,189 | +8.5% | |
| Total COGS | 7,180 | 8,086 | 10,186 | 9,917 | 8,989 | 10,327 | 12,616 | +9.8% |
| Gross Profit | 4,606 | 5,313 | 6,397 | 6,931 | 9,468 | 5,029 | 6,573 | +6.1% |
| Gross Margin | 39.1% | 39.7% | 38.6% | 41.1% | 51.3% | 32.8% | 34.3% | |
| 3,614 | 4,350 | 4,940 | 5,311 | 6,368 | 6,336 | 6,950 | +11.5% | |
| EBITDA | 992 | 963 | 1,456 | 1,620 | 3,100 | 1,307 | 376 | nmf |
| EBITDA Margin | 8.4% | 7.2% | 8.8% | 9.6% | 16.8% | 8.5% | 2.0% | |
| Total D&A | 100 | 100 | 111 | 102 | 129 | 148 | 141 | +5.9% |
| EBIT / Operating Income | 892 | 863 | 1,345 | 1,518 | 2,971 | 1,455 | 517 | nmf |
| Total Interest Income | 0 | 5 | 6 | 5 | 6 | 15 | 21 | +35.4% |
| Total Interest Expense | 25 | 29 | 34 | 24 | 14 | 6 | 1 | -41.2% |
| 15 | 2 | 11 | 21 | 97 | 6 | 41 | +17.8% | |
| Profit Before Tax | 852 | 837 | 1,307 | 1,477 | 2,866 | 1,452 | 539 | nmf |
| Total Income Tax | 0 | 0 | 0 | 0 | 392 | 0 | 50 | -64.3% |
| Net Profit / (Loss) | 971 | 837 | 1,307 | 1,477 | 2,474 | 1,452 | 589 | nmf |
| Net Margin | 8.2% | 6.2% | 7.9% | 8.8% | 13.4% | 9.5% | 3.1% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set.